AstraZeneca Seeks Cmte. Input On Further Iressa Marketing Steps

AstraZeneca publishing "Dear Doctor" letter on failed survival study results in oncology journals for foreseeable future. Efforts to inform physicians of trial results have led to a "substantial reduction" in new prescriptions for gefitinib, company says.